Results 31 to 40 of about 1,759,457 (222)

Pathways towards human immunodeficiency virus elimination

EBioMedicine, 2020
Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents.
Prasanta K. Dash, Bhavesh D. Kevadiya, Hang Su, Mary G. Banoub, Howard E. Gendelman   +4 more
doaj   +1 more source

Optimal control of an HIV model with gene therapy and latency reversing agents

, 2022
In this project, we study the dynamics of HIV under gene therapy and latency reversing agents. For constant treatment controls, we establish global stability of the disease-free equilibrium and endemic equilibrium based on the value of the basic ...
Hazelton, Paul, Grant, Andrew, Grant, Andrew B   +2 more
core   +1 more source

Engineering CAR T Cells to Target the HIV Reservoir

Frontiers in Cellular and Infection Microbiology, 2020
The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that ...
Wenli Mu, Mayra A. Carrillo, Scott G. Kitchen   +2 more
doaj   +1 more source

PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element

Cells, 2022
At present, the barrier to HIV-1 functional cure is the persistence of HIV-1 reservoirs. The “shock (reversing latency) and kill (antiretroviral therapy)” strategy sheds light on reducing or eliminating the latent reservoir of HIV-1. However, the current
Xinfeng Xu, Yingtong Lin, Xiaoyun Zeng, Chan Yang, Siqin Duan, Liqiong Ding, Wanzhen Lu, Jian Lin, Xiaoyan Pan, Xiancai Ma, Shuwen Liu   +10 more
doaj   +1 more source

Lnc(ing)RNAs to the “shock and kill” strategy for HIV-1 cure

Molecular Therapy: Nucleic Acids, 2021
The advent of antiretroviral therapy almost 25 years ago has transformed HIV-1 infection into a manageable chronic condition, albeit still incurable. The inability of the treatment regimen to eliminate latently infected cells that harbor the virus in an ...
Saikat Boliar, David G. Russell
doaj   +1 more source

Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling

, 2017
International audienceIn this study, we looked for a new family of latency reversing ...
Campos, Noëlie, Pierre Corbeau, Maurel, Damien, Sandrine Gimenez, Comps-Agrar, Laetitia, Prézeau, Laurent, Etienne Doumazane, Laetitia Comps-Agrar, Gimenez, Sandrine, Clément Mettling, Benjamin Viala, Caroline Boulouis, Laurent Prézeau, Duquenne, Charline, Charline Duquenne, Jamal Tazi, Boulouis, Caroline, Psomas, Christina, François, Vincent, Noëlie Campos, Doumazane, Etienne, Damien Maurel, Viala, Benjamin, Guigues, Adeline, Tazi, Jamal, Corbeau, Pierre, Vincent François, Christina Psomas, Adeline Guigues, Mettling, Clément   +29 more
core   +1 more source

Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. [PDF]

J Virol, 2017
Antiretroviral-free HIV remission requires substantial reduction of the number of latently infected cells and enhanced immune control of viremia.
Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.   +4 more
europepmc   +2 more sources

Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution

Frontiers in Microbiology, 2018
Identifying the source and dynamics of persistent HIV-1 at single-cell resolution during cART is crucial for the design of strategies to eliminate the latent HIV-1 reservoir.
Wang Zhang, Wang Zhang, Sara Svensson Akusjärvi, Anders Sönnerborg, Anders Sönnerborg, Ujjwal Neogi   +5 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

De Novo synthesis of VP16 coordinates the exit from HSV latency in vivo [PDF]

, 2009
The mechanism controlling the exit from herpes simplex virus latency (HSV) is of central importance to recurrent disease and transmission of infection, yet interactions between host and viral functions that govern this process remain unclear. The cascade
Sawtell, N.M., Thompson, R.L., Richard L Thompson, Chris M Preston, Nancy M Sawtell, Preston, C.M.   +5 more
core   +1 more source